DrugCite
Search

METASTRON

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Metastron Adverse Events Reported to the FDA Over Time

How are Metastron adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Metastron, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Metastron is flagged as the suspect drug causing the adverse event.

Most Common Metastron Adverse Events Reported to the FDA

What are the most common Metastron adverse events reported to the FDA?

Anaemia
93 (8.56%)
Condition Aggravated
80 (7.37%)
Platelet Count Decreased
57 (5.25%)
Disease Progression
44 (4.05%)
Disseminated Intravascular Coagulat...
41 (3.78%)
White Blood Cell Count Decreased
26 (2.39%)
Bone Marrow Failure
25 (2.3%)
Malignant Neoplasm Progression
23 (2.12%)
No Adverse Event
21 (1.93%)
General Physical Health Deteriorati...
18 (1.66%)
Nausea
16 (1.47%)
Show More Show More
Pain
16 (1.47%)
Neoplasm Progression
15 (1.38%)
Haemoglobin Decreased
14 (1.29%)
Hot Flush
14 (1.29%)
Bone Pain
13 (1.2%)
Prostate Cancer
13 (1.2%)
Pyrexia
13 (1.2%)
Death
12 (1.1%)
Diarrhoea
12 (1.1%)
Pneumonia
11 (1.01%)
Interstitial Lung Disease
9 (.83%)
Malaise
9 (.83%)
Metastatic Pain
9 (.83%)
Sepsis
9 (.83%)
Asthenia
8 (.74%)
Depressed Level Of Consciousness
8 (.74%)
Lung Neoplasm Malignant
8 (.74%)
Prostate Cancer Metastatic
8 (.74%)
Thrombocytopenia
8 (.74%)
Metastases To Liver
7 (.64%)
Vomiting
7 (.64%)
Blood Albumin Decreased
6 (.55%)
Blood Pressure Decreased
6 (.55%)
Decreased Appetite
6 (.55%)
Headache
6 (.55%)
Pancytopenia
6 (.55%)
Protein Total Decreased
6 (.55%)
Back Pain
5 (.46%)
Breast Cancer Female
5 (.46%)
Delirium
5 (.46%)
Gastrointestinal Haemorrhage
5 (.46%)
Hepatic Function Abnormal
5 (.46%)
Malignant Pleural Effusion
5 (.46%)
Red Blood Cell Count Decreased
5 (.46%)
Respiratory Failure
5 (.46%)
Anorexia
4 (.37%)
Bone Marrow Tumour Cell Infiltratio...
4 (.37%)
Breast Cancer Metastatic
4 (.37%)
Colon Cancer
4 (.37%)
Concomitant Disease Aggravated
4 (.37%)
Dyspnoea
4 (.37%)
Gait Disturbance
4 (.37%)
Metastases To Bone
4 (.37%)
Oesophageal Candidiasis
4 (.37%)
Pleural Effusion
4 (.37%)
Somnolence
4 (.37%)
Subdural Haemorrhage
4 (.37%)
Urinary Tract Infection
4 (.37%)
Abdominal Pain Upper
3 (.28%)
Acute Respiratory Distress Syndrome
3 (.28%)
Anorectal Disorder
3 (.28%)
Bladder Disorder
3 (.28%)
Blood Alkaline Phosphatase Increase...
3 (.28%)
Blood Calcium Increased
3 (.28%)
Blood Urea Increased
3 (.28%)
Cerebral Infarction
3 (.28%)
Cholecystitis
3 (.28%)
Constipation
3 (.28%)
Dehydration
3 (.28%)
Dementia
3 (.28%)
Dizziness
3 (.28%)
Eating Disorder
3 (.28%)
Fall
3 (.28%)
Fatigue
3 (.28%)
Gastritis
3 (.28%)
Haematuria
3 (.28%)
Hypercalcaemia
3 (.28%)
Hypoaesthesia
3 (.28%)
Leukaemia
3 (.28%)
Lung Cancer Metastatic
3 (.28%)
Monoplegia
3 (.28%)
Multi-organ Failure
3 (.28%)
Neoplasm Malignant
3 (.28%)
Oedema
3 (.28%)
Pathological Fracture
3 (.28%)
Prostatic Specific Antigen Increase...
3 (.28%)
Pulmonary Oedema
3 (.28%)
Septic Shock
3 (.28%)
Tumour Haemorrhage
3 (.28%)
Acute Myeloid Leukaemia
2 (.18%)
Acute Promyelocytic Leukaemia
2 (.18%)
Alanine Aminotransferase Increased
2 (.18%)
Altered State Of Consciousness
2 (.18%)
Alveolitis Allergic
2 (.18%)
Aspartate Aminotransferase Increase...
2 (.18%)
Blood Glucose Increased
2 (.18%)
Blood Potassium Increased
2 (.18%)
Blood Sodium Decreased
2 (.18%)
Breast Cancer
2 (.18%)
Cachexia
2 (.18%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Metastron, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Metastron is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Metastron

What are the most common Metastron adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Metastron, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Metastron is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Metastron According to Those Reporting Adverse Events

Why are people taking Metastron, according to those reporting adverse events to the FDA?

Metastatic Pain
312
Metastases To Bone
21
Bone Pain
14
Therapeutic Procedure
4
Metastasis
3
Prostate Cancer
3
Show More Show More
Product Used For Unknown Indication
1
Drug Use For Unknown Indication
1
Diagnostic Procedure
1
Breast Cancer Metastatic
1
Analgesic Effect
1
Photon Radiation Therapy To Bone
1

Metastron Case Reports

What Metastron safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Metastron. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Metastron.